flowchart TD
A["SUMO Precursor"] --> B["SENP Processing"]
B --> C["Mature SUMO"]
C --> D["SAE E1"]
D --> E["Ubc9 E2"]
E --> F["Target Protein"]
F --> G["Altered Localization"]
F --> H["Modified Activity"]
F --> I["Changed Stability"]
J["Cellular Stress"] -->|"Increase"| K["Global SUMOylation"]
J -->|"Increase"| L["DeSUMOylation via SENPs"]
M["Aβ/α-Syn/Tau"] -.->|Alter| K
N["Neurodegeneration"]-.->|Dysregulate| I
style J fill:#ffcdd2
style M fill:#ffcdd2
style N fill:#ffcdd2
SUMOylation is a reversible post-translational modification involving Small Ubiquitin-like Modifier (SUMO) proteins. This pathway plays crucial roles in protein stability, localization, and function, with dysregulation implicated in multiple neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS).
| Property | Value | Mechanism | Reference
|----------|-------|-----------|
| Modifier | SUMO (1, 2, 3, 4) | Conjugation |
| E1 Enzyme | SAE1/UBA2 | ATP-dependent activation |
| E2 Enzyme | UBC9 | Direct substrate conjugation |
| E3 Ligases | PIAS1/2/3/4, RanBP2, others | Substrate specificity |
| Target | Lysine residues (ΨKxE motif) | Covalent modification |
| Reversal | SENP1-7 proteases | Deconjugation |
The SUMOylation pathway proceeds through a well-defined enzymatic cascade 1:
- E1 - Activating enzyme: SAE1/UBA2 heterodimer activates SUMO in an ATP-dependent manner
- E2 - Conjugating enzyme: UBC9 directly transfers SUMO to target proteins, conferring specificity
- E3 - Ligases: PIAS family proteins (PIAS1, PIASx, PIASy, PIASL), RanBP2, and others provide substrate specificity
- SENPs: SUMO-specific proteases (SENP1-7) remove SUMO for reversibility and maturation
The canonical SUMOylation consensus sequence is ΨKxE (where Ψ is a hydrophobic residue like I, L, V). Additional motifs include:
- Reverse consensus: DxEΨK
- Phosphorylated SUMO consensus: (SP/TP)xK (where S/T are phosphorylated)
- Non-canonical sites: Various lysine residues can be modified
Four SUMO isoforms exist in humans:
- SUMO1: Widely expressed, forms monomeric conjugates
- SUMO2/3: Highly similar, form poly-SUMO chains
- SUMO4: Predominantly expressed in kidney and immune cells
SUMOylation regulates protein homeostasis through multiple mechanisms 2:
Proteasomal Degradation:
- SUMO chains can signal for proteasomal degradation (SUMO-dependent targeting)
- Crosstalk with ubiquitination: SUMOylated proteins can be ubiquitinated
- PML nuclear bodies serve as processing centers for damaged proteins
Autophagy:
- Selective autophagy of SUMOylated substrates 3
- p62/SQSTM1 recognizes SUMOylated proteins
- Autophagic clearance of aggregates
Protein Solubility:
- SUMO maintains protein solubility and prevents aggregation 4
- SUMOylation can mask hydrophobic patches
- Disaggregation functions through SUMO-targeted AAA ATPases
SUMOylation affects gene expression through multiple mechanisms 5:
Histone Modification:
- Histone H3 and H4 SUMOylation promotes repressive chromatin states
- Interaction with heterochromatin protein 1 (HP1)
- Recruitment of histone deacetylases
Transcription Factor Modulation:
- Many transcription factors are regulated by SUMOylation
- Repressive SUMOylation of REST, NCoR, SMRT
- Activation of some factors through SUMOylation
Co-activator/Co-repressor Function:
- Transcriptional co-regulators modified by SUMO
- Altered interaction with DNA binding proteins
- Nuclear receptor co-activators regulated
SUMOylation plays crucial roles in nuclear organization 6:
Nuclear Pore Complex:
- NPC proteins SUMOylated in stress conditions
- Nuclear transport regulated by SUMO
- Implications for mRNA export
PML Nuclear Bodies:
- Formation and function depend on SUMOylation
- Sites for protein quality control
- Dysregulation in neurodegeneration
SUMO impacts mitochondrial biology significantly 3:
Dynamics:
- Fusion/fission regulators (Mfn1/2, OPA1, Drp1) modified
- Mitochondrial morphology affected
Import:
- Protein trafficking into mitochondria altered
Quality Control:
- Mitophagy regulation through PINK1/Parkin pathway 7
- Mitochondrial protein quality control
SUMOylation of APP influences amyloid-beta generation 2:
- SUMOylation at K587 reduces amyloidogenic processing
- PIAS1-mediated SUMOylation decreases amyloid-beta secretion
- UBC9 overexpression reduces Aβ production
- Dysregulation contributes to amyloid plaque formation
- Aβ peptide interacts with SUMO-2/3, inhibiting its activity 4
SUMOylation promotes tau aggregation 8:
- SUMOylated tau is more prone to form neurofibrillary tangles
- SENP1 overexpression reduces tau aggregation
- SUMOylation affects tau phosphorylation status
- SUMOylation affects tau degradation pathways
- SUMO1 and SUMO2/3 show different effects on tau
SUMOylation modulates synaptic protein turnover:
- Synaptic receptors and scaffolding proteins are SUMO targets
- NMDA receptor SUMOylation regulates synaptic plasticity
- PSD-95 SUMOylation affects synaptic stability
- GluA1/2 AMPA receptor subunits modified
- Synaptic vesicle proteins regulated
SUMOylation intersects with inflammatory pathways:
- NF-κB SUMOylation modulates inflammatory gene expression
- Glial cell function affected
- Cytokine production regulated
SUMOylation affects alpha-synuclein pathology:
- SUMO1 conjugation reduces aggregation but may impair clearance
- SUMO2/3 conjugation promotes inclusions
- Differential effects of SUMO isoforms
- Parkin E3 ligase activity modulated by SUMOylation
- ZSCAN21 mediates transcriptional induction of α-syn 9
¶ Parkin and PINK1
The PINK1/Parkin mitophagy pathway involves SUMOylation 7:
- PINK1 stabilizes on damaged mitochondria
- Parkin SUMOylation enhances its E3 ligase activity
- SENP5 regulates mitochondrial dynamics through deSUMOylation
- Mitophagy initiation depends on SUMOylation status
- Mitochondrial clearance affected
Oxidative stress sensor DJ-1 is regulated by SUMOylation:
- SUMOylation protects against oxidative stress
- Parkinson's disease-associated mutations affect SUMOylation
- Cysteine 106 mutation (L166P) alters SUMOylation
- Therapeutic strategies target DJ-1 SUMOylation
- Neuroprotective function mediated by SUMO
LRRK2 mutations in PD:
- LRRK2 SUMOylation affects kinase activity
- Nuclear localization modulated
- Risk-associated mutations alter SUMO patterns
SUMOylation of mutant huntingtin 10:
- Promotes protein aggregation
- Increases toxicity
- Affects nuclear localization
- Multiple SUMOylation sites identified
- HAP40 trafficking affected
SUMOylation affects gene expression:
- Histone SUMOylation promotes repressive chromatin states
- Transcription factor SUMOylation alters target gene expression
- Coactivator/co-repressor SUMOylation modulates transcriptional programs
- REST SUMOylation in HD
- BDNF expression affected
SUMOylation impacts mitochondrial health:
- Mitochondrial proteins are SUMO targets
- Mitophagy regulators modified by SUMO
- Energy metabolism affected
- PGC-1α transcriptional activity modulated
TDP-43 aggregates in most ALS cases 11:
- SUMOylation influences TDP-43 aggregation 12
- SENP1 can reduce TDP-43 inclusions
- Nuclear export regulated by SUMOylation
- Stress granule dynamics affected
- Cytoplasmic mislocalization influenced
ALS-associated SOD1 mutations:
- SUMOylation affects mutant SOD1 stability
- Aggregate formation influenced by SUMO
- Therapeutic targeting possible
- Different mutations show distinct SUMO patterns
FUS pathology in ALS/FTD:
- SUMOylation affects nuclear import/export
- Stress granule dynamics regulated
- Mutations affect SUMOylation patterns
- TLS/FUS interactions with SUMO machinery
¶ SUMOylation and Ubiquitination
Complex interplay between SUMO and ubiquitin pathways 13:
- SUMO-targeted ubiquitin ligases (STUbLs) recognize SUMOylated proteins
- Crosstalk determines degradation pathways
- Hybrid chains possible
¶ SUMOylation and Phosphorylation
Kinetic regulation through phosphorylation:
- Phosphorylation creates SUMOylation sites
- CK2, GSK3β modulate SUMOylation
- Signal-dependent modification
¶ SUMOylation and ISGylation
Crosstalk with interferon-stimulated genes 13:
- ISG15 competes with SUMO
- Antiviral response intersection
- Implications for neuroinflammation
| Approach |
Target |
Potential |
Development Status |
| E1/E2 agonists |
SUMOylation enzymes |
Neuroprotection |
Preclinical |
| SENP inhibitors |
DeSUMOylation |
Reduce aggregation |
Research 14 |
| Gene therapy |
SUMO expression |
Experimental |
Early research |
| UBC9 enhancers |
E2 enzyme |
Increase SUMO |
Preclinical |
- α-Synuclein: Prevent harmful SUMOylation patterns
- Tau: Promote protective modifications
- Huntingtin: Reduce aggregation-prone forms
- TDP-43: Modulate aggregation propensity
Small molecules targeting SUMOylation:
- TAK-981 (subasumstat): Phase 1/2 for cancer, potential for neurodegeneration
- Various SENP inhibitors in development
- Natural compounds targeting SUMO pathway
- SENP1 expression: Potential biomarker in CSF
- SUMOylated protein levels: Correlation with disease stage
- UBC9 activity: Therapeutic response marker
- Specificity: Achieving substrate-specific modulation
- Delivery: Targeting SUMO pathway components in neurons
- Isoform specificity: Targeting specific SUMO isoforms
- Monitoring: Measuring SUMOylation in vivo
- Crosstalk understanding: Full complexity of modification interplay
- Clinical trials: SENP inhibitors for neurodegeneration
- Biomarker development: Patient stratification based on SUMO status
- Combination therapy: SUMO modulation with other approaches
- Gene therapy: Viral vector delivery of SUMO machinery
- Personalized medicine: SUMO patterns guiding treatment
The study of SUMOylation in neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding:
- Discovery of SUMO conjugation in 1990s
- Identification of SUMO in neuronal function
- Recognition of SUMO dysregulation in neurodegenerative diseases
- Development of SENP inhibitors as therapeutic agents